TRCT
RNAC icon

Tower Research Capital (TRC)’s Cartesian Therapeutics RNAC Stock Holding History

Tower Research Capital (TRC)’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7K Sell
1,747
-632
-27% -$4.5K ﹤0.01% 3875
2025
Q4 		$17.2K Buy
2,379
+1,067
+81% +$8.63K ﹤0.01% 3218
2025
Q3 		$13.4K Sell
1,312
-1,673
-56% -$18.8K ﹤0.01% 3684
2025
Q2 		$31K Buy
2,985
+704
+31% +$7.5K ﹤0.01% 3372
2025
Q1 		$30.1K Buy
2,281
+1,658
+266% +$29.6K ﹤0.01% 2609
2024
Q4 		$11.2K Buy
623
+56
+10% +$1.13K ﹤0.01% 3742
2024
Q3 		$9.14K Sell
567
-1,198
-68% -$18.7K ﹤0.01% 3899
2024
Q2 		$47.7K Buy
1,765
+1,527
+642% +$36.4K ﹤0.01% 3138
2024
Q1 		$4.64K Sell
238
-217
-48% -$4.6K ﹤0.01% 4651
2023
Q4 		$9.41K Buy
455
+75
+20% +$2.24K ﹤0.01% 4390
2023
Q3 		$12.1K Sell
380
-22
-5% -$735 ﹤0.01% 3927
2023
Q2 		$13.5K Sell
402
-346
-46% -$12.4K ﹤0.01% 3763
2023
Q1 		$31K Sell
748
-762
-50% -$35.8K ﹤0.01% 2967
2022
Q4 		$51K Sell
1,510
-577
-28% -$24.5K ﹤0.01% 2335
2022
Q3 		$102K Buy
2,087
+559
+37% +$30.7K ﹤0.01% 2551
2022
Q2 		$60K Sell
1,528
-1,332
-47% -$39.5K ﹤0.01% 2719
2022
Q1 		$106K Buy
2,860
+2,446
+591% +$153K ﹤0.01% 2157
2021
Q4 		$41K Sell
414
-134
-24% -$14.4K ﹤0.01% 2924
2021
Q3 		$68K Buy
548
+157
+40% +$19K ﹤0.01% 2715
2021
Q2 		$49K Sell
391
-145
-27% -$17.3K ﹤0.01% 3046
2021
Q1 		$73K Sell
536
-1,076
-67% -$134K ﹤0.01% 2826
2020
Q4 		$147K Sell
1,612
-575
-26% -$49.9K ﹤0.01% 2002
2020
Q3 		$163K Buy
2,187
+2,075
+1,853% +$159K ﹤0.01% 2758
2020
Q2 		$10K Buy
+112
New +$10.2K ﹤0.01% 4019
2020
Q1 		– Sell
-405
Closed -$29K – 3767
2019
Q4 		$29K Buy
405
+403
+20,150% +$19.4K ﹤0.01% 1686
2019
Q3 		$0 Sell
2
-116
-98% -$6.16K ﹤0.01% 4455
2019
Q2 		$7K Buy
+118
New +$8.04K ﹤0.01% 2786
2019
Q1 		– Sell
-417
Closed -$34K – 4203
2018
Q4 		$34K Buy
417
+343
+464% +$78.3K ﹤0.01% 1553
2018
Q3 		$35K Buy
74
+73
+7,300% +$29.3K ﹤0.01% 1985
2018
Q2 		$1K Sell
1
-13
-93% -$4.61K ﹤0.01% 3508
2018
Q1 		$4K Sell
14
-101
-88% -$28.8K ﹤0.01% 2805
2017
Q4 		$34K Buy
115
+46
+67% +$20.1K ﹤0.01% 1640
2017
Q3 		$37K Sell
69
-14
-17% -$7.45K ﹤0.01% 2249
2017
Q2 		$50K Buy
+83
New +$36.7K 0.01% 751
2017
Q1 		– Sell
-18
Closed -$9K – 3783
2016
Q4 		$9K Buy
18
+4
+29% +$2.34K ﹤0.01% 2725
2016
Q3 		$6K Buy
+14
New +$5.47K ﹤0.01% 2442

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s RNAC Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Cartesian Therapeutics (RNAC) stake by 27% in Q1 2026, selling an estimated $4.5K and leaving 1,747 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3875.

Tower Research Capital (TRC) first reported a position in RNAC in Q3 2016 and has held it in 36 quarters since. The position peaked at $163K in Q3 2020. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Tower Research Capital (TRC) held 1,747 shares of Cartesian Therapeutics worth $10.7K as of Q1 2026.
  • Tower Research Capital (TRC) sold 632 Cartesian Therapeutics shares in Q1 2026, an estimated $4.5K.
  • Cartesian Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3875 holding.
  • Tower Research Capital (TRC) first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 36 quarters since.
  • Tower Research Capital (TRC)'s Cartesian Therapeutics position peaked at $163K in Q3 2020.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.